JP2009540004A5 - - Google Patents

Download PDF

Info

Publication number
JP2009540004A5
JP2009540004A5 JP2009515526A JP2009515526A JP2009540004A5 JP 2009540004 A5 JP2009540004 A5 JP 2009540004A5 JP 2009515526 A JP2009515526 A JP 2009515526A JP 2009515526 A JP2009515526 A JP 2009515526A JP 2009540004 A5 JP2009540004 A5 JP 2009540004A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
carbamoyl
alkylamino
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009515526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009540004A (ja
Filing date
Publication date
Priority claimed from US11/455,202 external-priority patent/US20070293575A1/en
Application filed filed Critical
Publication of JP2009540004A publication Critical patent/JP2009540004A/ja
Publication of JP2009540004A5 publication Critical patent/JP2009540004A5/ja
Pending legal-status Critical Current

Links

JP2009515526A 2006-06-15 2007-06-14 癌の貧血の治療のためのｈｉｆヒドロキシラーゼ阻害剤 Pending JP2009540004A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/455,202 US20070293575A1 (en) 2006-06-15 2006-06-15 Compounds and methods for treatment of cancer-related anemia
PCT/US2007/014157 WO2007146438A1 (en) 2006-06-15 2007-06-14 Hif hydroxylase inhibitors for treatment of anemia of cancer

Publications (2)

Publication Number Publication Date
JP2009540004A JP2009540004A (ja) 2009-11-19
JP2009540004A5 true JP2009540004A5 (https=) 2011-03-10

Family

ID=38571332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515526A Pending JP2009540004A (ja) 2006-06-15 2007-06-14 癌の貧血の治療のためのｈｉｆヒドロキシラーゼ阻害剤

Country Status (7)

Country Link
US (2) US20070293575A1 (https=)
EP (1) EP2035000A1 (https=)
JP (1) JP2009540004A (https=)
CN (1) CN101500569A (https=)
AU (1) AU2007258213A1 (https=)
IL (1) IL195816A0 (https=)
WO (1) WO2007146438A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
BRPI0707302B8 (pt) * 2006-01-27 2021-05-25 Fibrogen Inc compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende
BRPI0710527B8 (pt) * 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
WO2009073669A1 (en) * 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
US8217043B2 (en) * 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
WO2010059549A1 (en) * 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
WO2011048611A1 (en) 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
TWI500623B (zh) 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
US8541430B2 (en) 2009-11-27 2013-09-24 Torrent Pharmaceuticals Limited Fused thiazolo and oxazolo pyrimidinones
EP2649182A4 (en) * 2010-12-10 2015-05-06 Alnylam Pharmaceuticals Inc Compositions and methods for increasing erythropoietin (epo) production
US20140057941A1 (en) * 2011-01-13 2014-02-27 Kin-Hung (Peony) Yu Methods For Increasing Mean Corpuscular Volume
US20140171465A1 (en) * 2011-01-13 2014-06-19 Fibrogen, Inc. Methods For Increasing Reticulocyte Hemoglobin Content
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
CN104024227B8 (zh) * 2011-07-22 2025-07-29 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
AU2013290438C1 (en) 2012-07-16 2019-01-03 Kyntra Bio, Inc. Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP3219706A1 (en) 2012-07-16 2017-09-20 Fibrogen, Inc. Process for making isoquinoline compounds
AU2014209319B2 (en) 2013-01-24 2018-04-19 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
HRP20200615T1 (hr) 2013-06-06 2020-07-10 Fibrogen, Inc. Farmaceutske formulacije inhibitora hif hidroksilaze
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2298301T3 (en) * 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005007183A2 (en) * 2003-07-17 2005-01-27 Thromb-X Nv Treatment of anemia
AU2006254897A1 (en) * 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
MX2007016160A (es) * 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.

Similar Documents

Publication Publication Date Title
JP2009540004A5 (https=)
JP2009540000A5 (https=)
JPH09124606A5 (https=)
KR950017970A (ko) 치환된 헤테로사이클릭 카복스아미드, 이의 제조방법 및 약제로서의 이의 용도
KR950014072A (ko) 치환된 헤테로사이클릭 카복스아미드, 이의 제조방법 및 약제로서의 이의 용도
US11680048B2 (en) Enhanced erythropoiesis and iron metabolism
KR950014069A (ko) 치환된 헤테로사이클릭 카복스아미드 에스테르, 이의 제조방법 및 약제로서의 이의 용도
US8530404B2 (en) Compounds and methods for treatment of cancer
AU2002362065B2 (en) Stabilization of hypoxia inducible factor (HIF) alpha
US20110015223A1 (en) Compounds and methods for treatment of cancer-related anemia
US20100331362A1 (en) Treatment method for anemia
US7713986B2 (en) Compounds and methods for treatment of chemotherapy-induced anemia
KR970061869A (ko) 치환된 퀴놀린-2-카복실산 아미드, 이의 제조방법 및 약제로서의 이의 용도와 중간체
KR950032124A (ko) 설폰아미도카보닐피리딘-2-카복스아미드 및 이의 피리딘-n- 옥사이드, 이의 제조방법 및 약제로서의 이의 용도
KR950032127A (ko) 치환된 헤테로사이클릭 카복스아미도에스테르, 이의 제조방법 및 약제로서의 이의 용도
US20140309256A1 (en) Therapeutic Method
KR950032125A (ko) 치환된 헤테로사이클릭 카복스아미드, 이의 제조방법 및 약제로서의 이의 용도
KR940009156A (ko) 아실설폰아미도피리딘-2-카복실산 에스테르와 설폰아미도 피리딘-2-카복실산 에스테르 및 이들의 피리딘 n-옥사이드, 이들의 제조 방법 및 약제로서의 이들의 용도